Clinical measures in transthyretin familial amyloid polyneuropathy

被引：53

作者：

Coelho, Teresa ^{[1
]}

Vinik, Aaron ^{[2
]}

Vinik, Etta J. ^{[2
]}

Tripp, Tara ^{[3
]}

Packman, Jeff ^{[4
]}

Grogan, Donna R. ^{[4
]}

机构：

[1] Hosp Santo Antonio, Ctr Hosp Porto, P-4099001 Oporto, Portugal

[2] Eastern Virginia Med Sch, Strelitz Diabet Ctr, Norfolk, VA 23501 USA

[3] DM Stat Inc, Malden, MA USA

[4] FoldRx Pharmaceut Inc, Cambridge, MA USA

来源：

MUSCLE & NERVE | 2017年 / 55卷 / 03期

关键词：

amyloidosis; modified body mass index; nerve fiber function; Neuropathy Impairment Score; Norfolk Quality of Life; ROCHESTER DIABETIC-NEUROPATHY; RETINOL-BINDING-PROTEIN; LIVER-TRANSPLANTATION; FOLLOW-UP; PERIPHERAL NEUROPATHY; END-POINTS; TAFAMIDIS; SURVIVAL; TRIAL; DYSFUNCTION;

D O I：

10.1002/mus.25257

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

IntroductionThis observational, cross-sectional, single-center study aimed to identify instruments capable of measuring disease progression in transthyretin familial amyloid polyneuropathy (TTR-FAP). MethodsThe relationship between disease stage and Neuropathy Impairment Score-Lower Limbs (NIS-LL) and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score was assessed in 61 (stages 1-3) patients with TTR-FAP (V30M variant) and 16 healthy controls. Composite measures of large- and small-nerve fiber function, and modified body mass index (mBMI) were also assessed. ResultsOrdinal-based NIS-LL and Norfolk QOL-DN scores discriminated between disease stages (P<0.0001 for NIS-LL and Norfolk QOL-DN). Longer disease duration correlated with worse NIS-LL and Norfolk QOL-DN. Karnofsky performance score declined progressively by disease stage. Composite measures of nerve fiber function differentiated stage 1 from stage 2 disease. The mBMI declined with advancing disease. ConclusionsNIS-LL, Norfolk QOL-DN score, composite endpoints of nerve fiber function, and mBMI are valid, reliable measures of TTR-FAP severity. Muscle Nerve55: 323-332, 2017

引用

页码：323 / 332

页数：10

共 41 条

[41] Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy The NATHAN 1 trial [J].

Ziegler, Dan ;

Low, Phillip A. ;

Litchy, William J. ;

Boulton, Andrew J. M. ;

Vinik, Aaron I. ;

Freeman, Roy ;

Samigullin, Rustem ;

Tritschler, Hans ;

Munzel, Ullrich ;

Maus, Joachim ;

Schutte, Klemens ;

Dyck, Peter J. .

DIABETES CARE, 2011, 34 (09) :2054-2060

← 1 2 3 4 5 →